18 -

r.o .. 0.... Files Anistreplase: in acute myocardial infarction Inflammatory response. neutrophil activation.

and free radical production after acute myocardial infarction: effect of thrombolytic treatment. Bell D. et al. British Heart Journal 63: 82. 1990

Anistreplase: pharmacology and biological data. Samama M. Archives des Maladies du Coeur et des Vaisseaux 83 (Spec. issue I): 15. 1990

Effects of thrombolytic agents on infarct size and left ventricular systolic function in myocardial infarction. Bassand JP. et al. Archives des Maladies du Coeur et des Vaisseaux 83 (Spec. issue I): 31. 1990

Long term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS Trial Study Group. Lancet 335: 427. 1990

New produl·t. Anistreplase. Drugs of Today 26: 7. 1990

Effect of anistreplase on coronary patency in acute myocardial infarction. Pacouret G. Charbonnier B. Archives des Maladies du Coeur et des Vaisseaux 83 (Spec. issue I): 25. 1990

Effect of anistreplase (Eminase) on survival after acute myocardial infarction. Murray RG. Archives des Maladies du Coeur et des Vaisseaux 83 (Spec. issue I): 37. 1990

Thrombolytic therapy and recurrent myocardial infarction. White HD. et al. New Zealand Medical Journal 103: 163. 1990

A multicenter trial of intravenous APSAC !"('rSIIS

rtPA in acute myocardial infarction. Assessment of efficacy and safety. Journal of the American Collge of Cardiology 15 (Suppl. A): 214. 1990

-\ni,()~lated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: results of a multicentre double blind trial versus heparin. Cassagnes J. et al. Archives des Maladies du Coeur et des Vaisseaux 83: 453. 1990

-\ systemic non-lytic state predicts failure of anisoylated plasminogen streptokinase activating complex in acute myocardial infarction. Brugemann J. et al. Journal of the American College of Cardiology 15 (Suppl. A): 3. 1990

Results of a randomized trial comparing APSAC and rTPA for the preservation of left ventricular function after acute myocardial infarction. Machecourt J. et al. Journal of the American College of Cardiolgoy 15 (Suppl. A): 64. 1990

Thrombolytic agents in unstable angina. Unasem Collaborative Group. Journal of the American College of Cardiology 15 (Suppl. A): 65. 1990

A multicenter trial of intravenous APSAC !"('nll.'

rtPA in acute m)ocardial infarction. Assessment of efficacy and safety. Journal of the American Collge of Cardiology 15 (Suppl. A): 214. 1990

16 MaJ' 1990 INPHARMA®

Quantitative assessment of coronary stenosis after thrombolySIS in acute myocardial infarction: results of a randomized study of anistreplase and streptokinase. Anderson JL. et al. Journal of the American College of Cardiology 15 (Suppl. A): 218.1990

Thrombolysis and intravenous beta-blockers in the acute phase of myocardial infarction. Jarry G. et al. Annales de Cardiologie et d' Angciologle 39: 83. 1990

Anistreplase introduced for therapy of acute

myocardial infarction. Clinical Pharmacy 9: 78. 1990

Coronary recanalisation with intravenous anistreplase (Eminase) in the acute phase of myocardial infarction. Monassier JP. et al. Archives des Maladies du Coeur et des Vaisseaux 83 (Spec. issue I): 21. 1990

Electrocardiographic evidence of myocardial salvage after thrombolysis in acute myocardial infarction. Hogg KJ. et al. British Heart Journal 61: 489. 1989

APSAC rs heparin for acute myocardial infarction: the German multicenter trial. Meinertz T, et al. Cardiovascular Reviews and Reports 10: 42. 1989

A randomized European multicentre study of APSAC !"('rsus streptokinase in myocardial infarction. Charbonnier B, et al. Archives des Maladies du Coeur et des Vaisseaux 82: 1565. 1989

Alteplase and anistreplase in acute myocardial infarction. Drug and Therapeutics Bulletin 27: 101. 1989

Pharmacokinetics. thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction. Col JJ. et al. American Journal of Cardiology 63: 1185, 1989

Relation of plasma D-Dimer concentrations to coronary artery reperfusion before and after thrombolytic treatmenl in patients With acute myocardial infarction. Brenner B. et al. American Journal of Cardiology 63: 1179, 1989

Reperfusion. patency and reocclusion with anistreplase (APSAC) in acute myocardial infarction. Anderson J L. American Journal of Cardiology 64: 12A. 1989

Limitation of myocardial infarct size and

preservation of left ventricular function bv early administration of APSAC in myocardial infarction. Bassand J-P. et al. American Journal of Cardiology 64: 18A. 1989

Increased sun ivai after APSAC: 30-day and 12-month mortality data from the APSAC intervention mortality study. Julian DG. American Journal of Cardiology 64: 27A. 1989

Prehospital use of -\PS-\C: results of a placebo­controlled study. Castaigne AD. et al. American Journal of Cardiology 64: 30A. 1989

Development of anisoy lated plasminogen­streptokinase activator complex from the acyl enzyme concept. Fears R. Seminars in Thrombosis and Hemostasis 15: 129. 1989

Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) l"('rSIIS intracoronary streptokinase in acute myocardial infarction. Hackworthy RA. et al. American Heart Journal 116: 903. 1988

Intravenous anisoylated plasminogen streptokinase activator complex (APSAC) ,'l'YSIIS intravenous streptokinase (SK) in

myocardial infarction (AM). A randomized multicenter study. Lopez-Sendon J. et al. European Heart Journal 9: 10. 1988

Efficacy and safet~ of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Takens LH. et al. European Heart Journal 9: 10. 1988

-\ multicenter double-blind trial of intravenous .-\PSAC rcrSIIS heparin in acute myocardial infarction. Final report of the APSI M study. Bassand JP. et al. Journal of the .American College of Cardiology II: 232A. 1988

Reduction of infarct size by intravenous APSAC in myocardial infarction (multicenter randomized trial n heparin). Cassagnes J. et al. European Heart Journal 9: 130. 1988

Use of thrombolytic therapy in a rural community outside hospital. McAleer B. Varma MPS. European Heart Journal 9: 135.1988

Reperfusion therapy of acute myocardial infarction. O'Neill W. et al. Progress in Cardiovascular Diseases 30: 235. 1988

Prehospital thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. Bossaert LL et al. Critical Care Medicine 16: 823. 1988

The German multicenter trial of anisoylated

plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Meinertz T. et al. American Journal of Cardiology 62: 347. 1988

~lulticenter reperfusion trial of intravenous aniso~ lated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. Anderson JL. et al. Journal of the American College of Cardiology II: 1153. 1988

Pharmacological profile and summary of clinical efficacy of .-\PSAC (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction. Grobe-Einsler R. Naunyn-Schmiedebcrg's Archives of Pharmacology 337: R69. 1988

Thrombolytic agents for acute evolving myocardial infarction: comparative effects. Sherry S. Rational Drug Thcrap~ 21: I. 1988

The acyl plasminogen-streptokinase complex in the acute phase of myocardial infarction. Results of a multicenter double-blind APSAC r('rSlIJ heparin trial. Cassagnes J, et al. Archives des Maladies du Coeur et des Vaisseaux 81: 125. 1988

Fibrinolytic drugs in acute myocardial infarction. Anon. Drug and Therapeutics Bulletin 26: 45. 1988

ISSN 0156-1703/90/0516-0018/0$01.00/0 © Adi! Internationall.td